Christensen M - Search Results

1

A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants.

Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, Ingelman-Sundberg M. Sim SC, et al. Among authors: christensen m. Clin Pharmacol Ther. 2006 Jan;79(1):103-13. doi: 10.1016/j.clpt.2005.10.002. Clin Pharmacol Ther. 2006. PMID: 16413245

2

Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19).

Christensen M, Tybring G, Mihara K, Yasui-Furokori N, Carrillo JA, Ramos SI, Andersson K, Dahl ML, Bertilsson L. Christensen M, et al. Clin Pharmacol Ther. 2002 Mar;71(3):141-52. doi: 10.1067/mcp.2002.121788. Clin Pharmacol Ther. 2002. PMID: 11907488 Clinical Trial.

3

Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans.

Ghotbi R, Christensen M, Roh HK, Ingelman-Sundberg M, Aklillu E, Bertilsson L. Ghotbi R, et al. Among authors: christensen m. Eur J Clin Pharmacol. 2007 Jun;63(6):537-46. doi: 10.1007/s00228-007-0288-2. Epub 2007 Mar 17. Eur J Clin Pharmacol. 2007. PMID: 17370067

4

The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes.

Christensen M, Andersson K, Dalén P, Mirghani RA, Muirhead GJ, Nordmark A, Tybring G, Wahlberg A, Yaşar U, Bertilsson L. Christensen M, et al. Clin Pharmacol Ther. 2003 Jun;73(6):517-28. doi: 10.1016/S0009-9236(03)00050-X. Clin Pharmacol Ther. 2003. PMID: 12811361 Clinical Trial.

5

Orally given melatonin may serve as a probe drug for cytochrome P450 1A2 activity in vivo: a pilot study.

Härtter S, Ursing C, Morita S, Tybring G, von Bahr C, Christensen M, Röjdmark S, Bertilsson L. Härtter S, et al. Among authors: christensen m. Clin Pharmacol Ther. 2001 Jul;70(1):10-6. doi: 10.1067/mcp.2001.116512. Clin Pharmacol Ther. 2001. PMID: 11452239

6

Intra-individual variability in urinary losartan oxidation ratio, an in vivo marker of CYP2C9 activity.

Yasar U, Dahl ML, Christensen M, Eliasson E. Yasar U, et al. Among authors: christensen m. Br J Clin Pharmacol. 2002 Aug;54(2):183-5. doi: 10.1046/j.1365-2125.2002.01646.x. Br J Clin Pharmacol. 2002. PMID: 12207639 Free PMC article. No abstract available.

7

Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine.

Carrillo JA, Christensen M, Ramos SI, Alm C, Dahl ML, Benitez J, Bertilsson L. Carrillo JA, et al. Among authors: christensen m. Ther Drug Monit. 2000 Aug;22(4):409-17. doi: 10.1097/00007691-200008000-00008. Ther Drug Monit. 2000. PMID: 10942180

8

The impact of CYP2C9 genetics and oral contraceptives on cytochrome P450 2C9 phenotype.

Sandberg M, Johansson I, Christensen M, Rane A, Eliasson E. Sandberg M, et al. Among authors: christensen m. Drug Metab Dispos. 2004 May;32(5):484-9. doi: 10.1124/dmd.32.5.484. Drug Metab Dispos. 2004. PMID: 15100169

9

Ontogeny of dextromethorphan O- and N-demethylation in the first year of life.

Blake MJ, Gaedigk A, Pearce RE, Bomgaars LR, Christensen ML, Stowe C, James LP, Wilson JT, Kearns GL, Leeder JS. Blake MJ, et al. Among authors: christensen ml. Clin Pharmacol Ther. 2007 Apr;81(4):510-6. doi: 10.1038/sj.clpt.6100101. Epub 2007 Feb 14. Clin Pharmacol Ther. 2007. PMID: 17301735

10

New Estimates of Nitrogen Fixation on Early Earth.

Christensen M, Adams D, Wong ML, Dunn P, Yung YL. Christensen M, et al. Life (Basel). 2024 May 8;14(5):601. doi: 10.3390/life14050601. Life (Basel). 2024. PMID: 38792622 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,296 results

Search Page